Cipla Q2 FY27 profit drops 35% to ₹878 crore on North America slump
Synopsis
Cipla's Q2 FY27 profit more than halved on a year-on-year basis, with North America revenue crashing 19% to $172 million and EBITDA margins shrinking to 18.7% from 25%. The silver lining: the India business hit an all-time quarterly sales record — but it wasn't enough to prevent the steepest earnings fall in recent memory.
Key Takeaways
Cipla Q2 FY27 net profit fell 35 per cent YoY to ₹878 crore from ₹1,351.17 crore .
Revenue from operations declined 2.4 per cent to ₹7,403.93 crore .
EBITDA dropped 26.8 per cent to ₹1,388 crore ; margin contracted 630 basis points to 18.7 per cent .
North America revenue fell 19 per cent to ₹1,643 crore ( $172 million ), the key drag on earnings.
India (One-India) business rose 12 per cent YoY to ₹3,516 crore , recording its highest-ever quarterly sales.
API and other businesses revenue plunged 59 per cent to ₹107 crore .
Pharmaceutical major Cipla on Tuesday, 27 October 2026 reported a 35 per cent year-on-year decline in consolidated net profit for the second quarter of FY27, as a sharp deterioration in North American sales and a steep contraction in operating margins weighed heavily on its performance.
Key Financial Figures
Cipla posted a net profit of ₹878 crore for the quarter ended September 2026, down from ₹1,351.17 crore in the corresponding quarter of FY26, according to its stock exchange filing. Revenue from operations also slipped 2.4 per cent to ₹7,403.93 crore from ₹7,589 crore a year ago.
Operating performance came under significant pressure. EBITDA fell 26.8 per cent to ₹1,388 crore from ₹1,895 crore in the year-ago period, while the EBITDA margin contracted by 630 basis points to 18.7 per cent from 25 per cent. Following the earnings release, Cipla shares were trading 0.6 per cent lower at ₹1,347 apiece in afternoon trade.
North America Drags Performance
The primary drag came from North America, where revenue declined 19 per cent year-on-year to ₹1,643 crore — equivalent to $172 million — from ₹2,039 crore in Q2 FY26. The region, historically one of Cipla's most profitable geographies, has faced pricing pressure and increased generic competition, a trend that has broadly affected Indian pharmaceutical exporters operating in the US market.
India Business Hits Record Quarterly Sales
Bucking the overall trend, Cipla's domestic business delivered a standout quarter. Revenue from the India market rose 12 per cent year-on-year to ₹3,516 crore from ₹3,146 crore. Notably, the company's One-India business recorded its highest-ever quarterly sales during the period, providing a meaningful counterweight to the overseas weakness.
Other Markets and Segment Performance
The One Africa business reported revenue of ₹1,171 crore, down 1 per cent year-on-year, with South Africa revenue declining 3 per cent to ₹872 crore. However, Cipla noted that its South African private business grew 1.3 times faster than the broader market. Revenue from emerging markets and Europe held largely flat at ₹967 crore, despite ongoing geopolitical uncertainties in several operating regions.
The sharpest sectoral decline came from the API and other businesses segment, where revenue plunged 59 per cent to ₹107 crore from ₹259 crore in the year-ago quarter — a signal of subdued demand in the active pharmaceutical ingredients supply chain.
What Comes Next
The results put pressure on Cipla's management to articulate a clear recovery roadmap for the North American business, where pricing dynamics and regulatory timelines continue to test margins across the sector. Analysts will closely watch whether the India momentum can offset overseas headwinds in the quarters ahead, and whether the API segment stabilises as inventory corrections in global supply chains run their course.
Point of View
Dr. Reddy's, and Aurobindo in successive quarters. The 630-basis-point margin collapse is particularly alarming because it suggests volume declines are being compounded by price erosion, not just one or the other. The record India quarter is genuinely impressive, but domestic pharma — however fast-growing — cannot yet absorb a 19% North America revenue hole. The real question for investors is whether Cipla has a credible near-term pipeline of complex generics or specialty products that can reset US margins, or whether it is managing a slow decline in its most profitable geography.
NationPress
27 Oct 2026
Frequently Asked Questions
What was Cipla's net profit in Q2 FY27?
Cipla reported a net profit of ₹878 crore in Q2 FY27 (quarter ended September 2026), a decline of 35 per cent compared to ₹1,351.17 crore in Q2 FY26. The fall was driven by weaker North America sales and a sharp contraction in operating margins.
Why did Cipla's profit fall so sharply?
The primary reasons were a 19 per cent decline in North America revenue to ₹1,643 crore and a 630-basis-point contraction in EBITDA margins to 18.7 per cent. Pricing pressure and generic competition in the US market were key factors, according to the company's filing.
How did Cipla's India business perform in Q2 FY27?
Cipla's India business was the standout performer, with revenue rising 12 per cent year-on-year to ₹3,516 crore. The One-India business recorded its highest-ever quarterly sales during the period.
What happened to Cipla's EBITDA in Q2 FY27?
EBITDA fell 26.8 per cent to ₹1,388 crore from ₹1,895 crore a year ago. The EBITDA margin contracted by 630 basis points to 18.7 per cent from 25 per cent in Q2 FY26.
How did Cipla's stock react to the Q2 results?
Cipla shares were trading 0.6 per cent lower at ₹1,347 apiece in afternoon trade on Tuesday following the earnings announcement.
